2023 brought significant changes to the healthcare landscape, encompassing the Inflation Reduction Act (IRA), navigating an unprecedented array of diagnostic policies and regulations, and managing the evolving financial environment. As a look back, we asked the ADVI team, “What was the biggest challenge or opportunity in the 2023 evolving healthcare landscape from your area of expertise?” Here’s what they shared.

Lindsay Bealor Greenleaf, federal and state policy solution leader at ADVI, shares that the IRA and government price controls at the federal and state levels were top focus areas this year.

Marc Samuels, ADVI CEO and president, discusses some of the biggest challenges from 2023 including the IRA and its impact on oncology.


Learn More

Stay ahead of the curve as you look toward 2024. Get in touch today to gain expert insights and strategic counsel on the evolving healthcare landscape.


Marc Samuels, JD, MPH
Chief Executive Officer

Lindsay Bealor Greenleaf, JD, MBA
Senior Vice President, Market Access and Policy Strategy

CEO insights

Real analysis from people who’ve been there

Medicare Negotiation Program Deselection: Analysis of Previously Deselected Drugs and Likely Fall 2026 Targets

Authored by Allison Schneider, MHA, and Lindsay Bealor Greenleaf, JD, MBA Under the Inflation Reduction Act, drugs selected for the …

November 4, 2026

Health Policy & Access Strategy Inflation Reduction Act

Exclusive Webinar: Unpacking the Future of U.S. Drug Pricing Policy

Gain immediate access to actionable insights from CMS and ADVI Health policy leaders. From the Medicare Drug Price Negotiation Program …

October 2, 2026

Health Policy & Access Strategy Inflation Reduction Act

Analysis of 340B modifier usage in Medicare Part B claims

Analysis of Part B Claims from January 2025 through June 2026 Prepared By:Johanna Celli, Pete Kardel, Caitlin Sheetz, ADVI Health’s …

September 30, 2026

The Growing Relevance of HEOR: Turning Complex Healthcare Questions Into Actionable Evidence

For the first time, ISPOR added “Relevance of HEOR: Demonstrating the Field’s Vital Role in Health” to its Top 10 …

September 24, 2026

Precision Medicine

CMS Proposes RAPID Coverage Pathway for Breakthrough Devices

IVDs remain outside scope, while FDA-CMS Parallel Review remains available. KEY TAKEAWAY RAPID could materially shorten the gap between Food …

August 21, 2026

ADVI Health Accelerates Insights with Monthly Medicare Data

ADVI Health now has access to 100% of Medicare Parts A, B, and D research files with monthly availability – …

August 12, 2026

Why Clinical Laboratories Should Consider Weighing In on CMS and CDC’s New CLIA Request for Information

An opportunity for laboratories to help shape the future of CLIA regulation On July 16, 2026, the Centers for Medicare …

July 27, 2026

RAND/UCLA Modified Delphi Panels

ADVI Health partners with pharmaceutical and biotech organizations to advance their evidence generation and market access strategies. We support complex research questions through primary research (e.g., …

Caitlin Sheetz, MPH
June 23, 2026

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.